The9 Ltd
NCTY
Bit Digital
BTBT
TeraWulf
WULF
Digihost Technology
DGHI
BTCS Inc
BTCS
US Stock MarketDetailed Quotes
LTRN Lantern Pharma
- 3.720
- +0.070+1.92%
Close Mar 27 16:00 ET
40.12MMarket Cap-1.93P/E (TTM)
3.970High3.650Low20.09KVolume3.652Open3.650Pre Close74.46KTurnover0.25%Turnover RatioLossP/E (Static)10.78MShares9.96052wk High1.89P/B29.62MFloat Cap2.79052wk Low--Dividend TTM7.96MShs Float24.840Historical High--Div YieldTTM8.76%Amplitude2.380Historical Low3.706Avg Price1Lot Size
Market Insights
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Lantern Pharma Stock Forum
START BUYING DRUG APPROVAL COMING SOON
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
Monday, 27th January at 7:55 am
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced advancements in the application of its RADR® AI platform to a...
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Monday, 9th December at 8:15 am
Multiple clinical trial sites across Taiwan are actively screening patients, following successful site initiation visits.
Expansion into Taiwan is particularly significant as over 50% of lung cancer cases in Taiwan occur in never-smokers.
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence...
5 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
Tuesday, 3rd December at 8:00 am
• This is the second Fast Track Designation granted to LP-184 in 2024, following the designation for Glioblastoma (GBM) announced in October 2024.
• Fast Track Designation for LP-184 recognizes TNBC as a serious condition impacting approximately 29,000 patients annually in th...
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma and its subsidiary Starlight Therapeutics presented new preclinical data and Phase 1b trial design for LP-184 (STAR-001) in glioblastoma at SNO 2024.
The data shows LP-184 combined with spironolactone increases GBM cell sensitivity up to 6-fold thro...
No comment yet